Hot Features
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboratio... Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0288 | -7.60295670539 | 0.3788 | 0.4 | 0.315 | 3012731 | 0.35473725 | CS |
| 4 | 0.0143 | 4.25975573429 | 0.3357 | 0.4 | 0.268 | 2207745 | 0.33670647 | CS |
| 12 | -0.1925 | -35.4838709677 | 0.5425 | 0.5438 | 0.25 | 3948472 | 0.33360846 | CS |
| 26 | -1.79 | -83.6448598131 | 2.14 | 2.25 | 0.25 | 3639123 | 0.47505803 | CS |
| 52 | -2.44 | -87.4551971326 | 2.79 | 3.69 | 0.25 | 1997905 | 0.67206111 | CS |
| 156 | -2.5 | -87.7192982456 | 2.85 | 8.94 | 0.25 | 1325501 | 0.77136713 | CS |
| 260 | -2.5 | -87.7192982456 | 2.85 | 8.94 | 0.25 | 1325501 | 0.77136713 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.